Literature DB >> 19164285

Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies.

Lionel M Igaz1, Linda K Kwong, Alice Chen-Plotkin, Matthew J Winton, Travis L Unger, Yan Xu, Manuela Neumann, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

The disease protein in frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS) was identified recently as the TDP-43 (TAR DNA-binding protein 43), thereby providing a molecular link between these two disorders. In FTLD-U and ALS, TDP-43 is redistributed from its normal nuclear localization to form cytoplasmic insoluble aggregates. Moreover, pathological TDP-43 is abnormally ubiquitinated, hyperphosphorylated, and N-terminally cleaved to generate C-terminal fragments (CTFs). However, the specific cleavage site(s) and the biochemical properties as well as the functional consequences of pathological TDP-43 CTFs remained unknown. Here we have identified the specific cleavage site, Arg(208), of a pathological TDP-43 CTF purified from FTLD-U brains and show that the expression of this and other TDP-43 CTFs in cultured cells recapitulates key features of TDP-43 proteinopathy. These include the formation of cytoplasmic aggregates that are ubiquitinated and abnormally phosphorylated at sites found in FTLD-U and ALS brain and spinal cord samples. Furthermore, we observed splicing abnormalities in a cell culture system expressing TDP-43 CTFs, and this is significant because the regulation of exon splicing is a known function of TDP-43. Thus, our results show that TDP-43 CTF expression recapitulates key biochemical features of pathological TDP-43 and support the hypothesis that the generation of TDP-43 CTFs is an important step in the pathogenesis of FTLD-U and ALS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164285      PMCID: PMC2659210          DOI: 10.1074/jbc.M809462200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5' splicing site.

Authors:  A F Muro; A Iaconcig; F E Baralle
Journal:  FEBS Lett       Date:  1998-10-16       Impact factor: 4.124

2.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

3.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

4.  Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation.

Authors:  Matthew J Winton; Lionel M Igaz; Margaret M Wong; Linda K Kwong; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2008-02-27       Impact factor: 5.157

5.  Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.

Authors:  E Buratti; F E Baralle
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

6.  TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing.

Authors:  Emanuele Buratti; Antonia Brindisi; Maurizio Giombi; Sergio Tisminetzky; Youhna M Ayala; Francisco E Baralle
Journal:  J Biol Chem       Date:  2005-09-12       Impact factor: 5.157

7.  Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.

Authors:  Pablo Arrisi Mercado; Youhna M Ayala; Maurizio Romano; Emanuele Buratti; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

8.  Structural determinants of the cellular localization and shuttling of TDP-43.

Authors:  Youhna M Ayala; Paola Zago; Andrea D'Ambrogio; Ya-Fei Xu; Leonard Petrucelli; Emanuele Buratti; Francisco E Baralle
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

9.  TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.

Authors:  Jemeen Sreedharan; Ian P Blair; Vineeta B Tripathi; Xun Hu; Caroline Vance; Boris Rogelj; Steven Ackerley; Jennifer C Durnall; Kelly L Williams; Emanuele Buratti; Francisco Baralle; Jacqueline de Belleroche; J Douglas Mitchell; P Nigel Leigh; Ammar Al-Chalabi; Christopher C Miller; Garth Nicholson; Christopher E Shaw
Journal:  Science       Date:  2008-02-28       Impact factor: 47.728

10.  Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.

Authors:  E Buratti; T Dörk; E Zuccato; F Pagani; M Romano; F E Baralle
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

View more
  167 in total

1.  Neurotoxic effects of TDP-43 overexpression in C. elegans.

Authors:  Peter E A Ash; Yong-Jie Zhang; Christine M Roberts; Tassa Saldi; Harald Hutter; Emanuele Buratti; Leonard Petrucelli; Christopher D Link
Journal:  Hum Mol Genet       Date:  2010-06-08       Impact factor: 6.150

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

Review 4.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

5.  Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA.

Authors:  Sang Hwa Kim; Naval P Shanware; Michael J Bowler; Randal S Tibbetts
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

6.  The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.

Authors:  Claudia Fallini; Gary J Bassell; Wilfried Rossoll
Journal:  Hum Mol Genet       Date:  2012-05-28       Impact factor: 6.150

7.  Phosphorylation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Truncated Casein Kinase 1δ Triggers Mislocalization and Accumulation of TDP-43.

Authors:  Takashi Nonaka; Genjiro Suzuki; Yoshinori Tanaka; Fuyuki Kametani; Shinobu Hirai; Haruo Okado; Tomoyuki Miyashita; Minoru Saitoe; Haruhiko Akiyama; Hisao Masai; Masato Hasegawa
Journal:  J Biol Chem       Date:  2016-01-14       Impact factor: 5.157

8.  Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43.

Authors:  Antonella Caccamo; Smita Majumder; Salvatore Oddo
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

9.  A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology.

Authors:  Takenari Yamashita; Takuto Hideyama; Kosuke Hachiga; Sayaka Teramoto; Jiro Takano; Nobuhisa Iwata; Takaomi C Saido; Shin Kwak
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

10.  Neurodegeneration-associated protein fragments as short-lived substrates of the N-end rule pathway.

Authors:  Christopher S Brower; Konstantin I Piatkov; Alexander Varshavsky
Journal:  Mol Cell       Date:  2013-03-14       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.